Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants.

ABSTRACT:

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with different antigenic variants, has posed a significant threat to public health. It is urgent to develop inhalable vaccines, instead of injectable vaccines, to elicit mucosal immunity against respiratory viral infections.

Methods

We reported an inhalable hybrid nanovaccine (NV_RBD-MLipo) to boost protective immunity against SARS-CoV-2 infection. Nanovesicles derived from genetically engineered 293T cells expressing RBD (NV_RBD) were fused with pulmonary surfactant (PS)-biomimetic liposomes containing MPLA (MLipo) to yield NV_RBD-MLipo, which possessed virus-biomimetic structure, inherited RBD expression and versatile properties.

Results

In contrast to subcutaneous

SUBMITTER: Wang S 

PROVIDER: S-EPMC10898168 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature